At the time of writing, Acadia Pharmaceuticals Inc [ACAD] stock is trading at $27.44, up 3.35%. An important factor to consider is whether the stock is rising or falling in short-term value. The ACAD shares have gain 9.58% over the last week, with a monthly amount glided 22.88%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Acadia Pharmaceuticals Inc [NASDAQ: ACAD] stock has seen the most recent analyst activity on October 21, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $33. Previously, Deutsche Bank upgraded its rating to Buy on May 21, 2025, and kept the price target unchanged to $35. On February 11, 2025, Deutsche Bank initiated with a Hold rating and assigned a price target of $22 on the stock. Guggenheim downgraded its rating to a Neutral and decreased its price target to $20 on January 03, 2025. Morgan Stanley downgraded its rating to Equal-Weight for this stock on August 07, 2024, and downed its price target to $20. In a note dated June 27, 2024, BMO Capital Markets initiated an Outperform rating and provided a target price of $31 on this stock.
For the past year, the stock price of Acadia Pharmaceuticals Inc fluctuated between $13.40 and $26.76. Currently, Wall Street analysts expect the stock to reach $28.75 within the next 12 months. Acadia Pharmaceuticals Inc [NASDAQ: ACAD] shares were valued at $27.44 at the most recent close of the market. An investor can expect a potential return of 4.77% based on the average ACAD price forecast.
Analyzing the ACAD fundamentals
According to Acadia Pharmaceuticals Inc [NASDAQ:ACAD], the company’s sales were 1.05B for trailing twelve months, which represents an 11.27% jump. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at 0.23%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.22%. To continue investigating profitability, this company’s Return on Assets is posted at 0.18, Equity is 0.31 and Total Capital is 0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.92 points at the first support level, and at 26.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.78, and for the 2nd resistance point, it is at 28.13.
Ratios To Look Out For
It is important to note that Acadia Pharmaceuticals Inc [NASDAQ:ACAD] has a current ratio of 3.02. On the other hand, the Quick Ratio is 2.94, and the Cash Ratio is 0.77. Considering the valuation of this stock, the price to sales ratio is 4.43, the price to book ratio is 5.06 and price to earnings (TTM) ratio is 17.65.
Transactions by insiders
Recent insider trading involved Schneyer Mark C., EVP, CHIEF FINANCIAL OFFICER, that happened on Nov 18 ’25 when 10262.0 shares were sold. PRINCIPAL ACCOUNTING OFFICER, Kihara James completed a deal on Nov 18 ’25 to sell 4084.0 shares. Meanwhile, Director Daly James M sold 30000.0 shares on Nov 10 ’25.
